These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19182242)

  • 21. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
    Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
    Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
    Kim SH; Kim H; Kim TS
    Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
    Griffin CA; Burger P; Morsberger L; Yonescu R; Swierczynski S; Weingart JD; Murphy KM
    J Neuropathol Exp Neurol; 2006 Oct; 65(10):988-94. PubMed ID: 17021403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
    Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
    Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
    Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
    Magnani I; Moroni RF; Roversi G; Beghini A; Pfundt R; Schoenmakers EF; Larizza L
    Cancer Genet Cytogenet; 2005 Sep; 161(2):140-5. PubMed ID: 16102584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiles associated with treatment response in oligodendrogliomas.
    French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA
    Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
    Miller CR; Dunham CP; Scheithauer BW; Perry A
    J Clin Oncol; 2006 Dec; 24(34):5419-26. PubMed ID: 17135643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors.
    Huang L; Jiang T; Yuan F; Li GL; Liu EZ; Wang ZC
    Clin Neurol Neurosurg; 2008 Dec; 110(10):1020-4. PubMed ID: 18845382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
    Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
    Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
    Ino Y; Betensky RA; Zlatescu MC; Sasaki H; Macdonald DR; Stemmer-Rachamimov AO; Ramsay DA; Cairncross JG; Louis DN
    Clin Cancer Res; 2001 Apr; 7(4):839-45. PubMed ID: 11309331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
    Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
    Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status.
    Eigenbrod S; Roeber S; Thon N; Giese A; Krieger A; Grasbon-Frodl E; Egensperger R; Tonn JC; Kreth FW; Kretzschmar HA
    J Neuropathol Exp Neurol; 2011 Nov; 70(11):970-8. PubMed ID: 22002423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
    McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
    Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical relevance of 1p19q codeletion of oligodendrogliomas at the Department of Neurosurgery in Debrecen].
    Klekner A; Fekete G; Rencsi M; Méhes G; Szabó P; Bognár L
    Ideggyogy Sz; 2012 Jan; 65(1-2):17-24. PubMed ID: 22338842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
    Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
    J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q.
    Tews B; Roerig P; Hartmann C; Hahn M; Felsberg J; Blaschke B; Sabel M; Kunitz A; Toedt G; Neben K; Benner A; von Deimling A; Reifenberger G; Lichter P
    Oncogene; 2007 Jul; 26(34):5010-6. PubMed ID: 17311001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.